jwiley, Author at ELIAS Animal Health

Promising New Data Demonstrates Chemo-Immunotherapy Treatment Approach with ECI® Significantly Improves Outcomes in Dogs with Bone Cancer

LENEXA, Kan. – September 23, 2025 – ELIAS Animal Health, a leader in advancing novel therapies for veterinary cancer care, has published new data from its ASCENT study evaluating a novel chemo-immunotherapy regimen for canine osteosarcoma, an aggressive and often fatal bone cancer in dogs. The analysis was recently presented at the 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities and will be discussed in detail at the upcoming 2025 Veterinary Cancer Society Annual Conference. The ASCENT study investigated a treatment strategy that integrates a single dose of chemotherapy followed by the ELIAS Cancer Immunotherapy (ECI®) to enhance the immune system’s ability to recognize and destroy cancer cells. ECI® is the first-ever approved therapy for the treatment of canine osteosarcoma, receiving licensure from the USDA Center for Veterinary Biologics earlier this year. Key outcomes from the study demonstrated that: This combination approach significantly [...]

jwiley2025-09-23T09:03:58-05:00September 23rd, 2025|

ELIAS Animal Health to Present New Research at Upcoming Human and Veterinary Oncology Conferences

LENEXA, Kan., September 4, 2025 -- ELIAS Animal Health, a leader in advancing innovative therapies for veterinary oncology, today announced that it will present promising new research on its novel chemo-immunotherapy approach for canine osteosarcoma at two upcoming scientific meetings in September 2025. 18th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities, being held September 18–21, 2025, in Baltimore, Md. The presentation will highlight the safety and efficacy of integrating traditional cytotoxic chemotherapy with a vaccine-enhanced adoptive cell therapy in canine osteosarcoma, a well-known translational model for pediatric osteosarcoma in humans. 2025 Veterinary Cancer Society Annual Conference, being held September 25–27, 2025, in Salt Lake City, Utah. The company’s findings will be shared in an oral presentation at the Research Spotlight Symposium on September 26, 2025. The presentation will focus on the clinical experience using this combination therapeutic strategy with its USDA-approved cancer immunotherapy [...]

jwiley2025-09-04T06:25:17-05:00September 4th, 2025|

Immunotherapy Combined with a Single Dose of Chemotherapy Shows Improved Outcomes in Dogs with Bone Cancer

Recently, ELIAS Animal Health announced new data on a chemo-immunotherapy approach using the ELIAS Cancer Immunotherapy (ECI®) to treat canine osteosarcoma that demonstrated improved outcomes. The analysis showed that combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI® has the potential to enhance overall response and survival rates in canine cancer patients. In the study, 14 dogs received one dose of carboplatin followed by ECI® initiated 21 days later. This treatment group showed the best response, with a 1-year survival rate of 71% compared to 21% in 14 matched control dogs that received four doses of carboplatin only. See the data>> An updated in-depth analysis of this combination approach with additional data will be presented at the 2025 Veterinary Cancer Society (VCS) Annual Conference in Salt Lake City, Utah. Jeffrey N Bryan, DVM, MS, PhD, DACVIM(O), who presented the first analysis at the 2025 [...]

jwiley2025-07-29T12:50:53-05:00July 24th, 2025|

New Study Data on Chemo-Immunotherapy Approach Using the ELIAS Cancer Immunotherapy (ECI®) to Treat Bone Cancer in Dogs Demonstrates Improved Outcomes

LENEXA, Kan., June 19, 2025 – ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced interim results from an ongoing clinical study evaluating ELIAS Cancer Immunotherapy (ECI®), a USDA-approved autologous prescription product, combined with chemotherapy for treatment of osteosarcoma, an aggressive form of bone cancer in dogs. The interim analysis, presented at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, KY, demonstrated that combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI® has the potential to enhance overall response and survival rates in canine cancer patients. The oral abstract presentation, “Adoptive Cell Therapy with Chemotherapy Improves Canine Osteosarcoma Outcomes Compared to Standard of Care Chemotherapy,” was presented by Jeffrey N Bryan, DVM, MS, PhD, DACVIM(O), Professor of Oncology and Associate Director of the Ellis Fischel Cancer Center at the University of Missouri. The combined therapeutic approach showed [...]

jwiley2025-06-19T12:22:31-05:00June 19th, 2025|

The Body’s Inner Army: How Immunotherapy Trains the Immune System to Battle Cancer

Cancer immunotherapies are treatments that help a patient’s own immune system find and destroy cancer cells. Normally, the immune system might not recognize cancer cells as a threat, but these therapies condition or “train” immune cells to spot certain features – called antigens – that are found on cancer cells. Once trained, the immune cells work together to target and eliminate the cancer. There are different types of immune cells, each with their own job. Let’s look at some of these cell types and the role they play in immune system function. First Line of Defense: Monocytes, Macrophages, and Dendritic Cells Monocytes, macrophages, and dendritic cells are key immune cells that act as the body’s first line of defense, quickly detecting and neutralizing threats while also helping to activate the rest of the immune system for a more targeted response. Monocytes travel through the bloodstream and are quick to respond [...]

jwiley2025-06-03T12:53:26-05:00June 3rd, 2025|

Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Joins ELIAS Animal Health Scientific Advisory Board

LENEXA, Kan., April 10, 2025 -- ELIAS Animal Health, a leading innovator in cancer immunotherapies for veterinary medicine, today announced that Dr. Philip J. Bergman, DVM, PhD, DACVIM (Oncology), has joined its Scientific Advisory Board. Philip J. Bergman, DVM, PhD, DACVIM (Oncology) Dr. Bergman brings extensive experience in veterinary oncology, immunotherapy, and translational medicine, with a distinguished career in clinical research and cancer treatment advancements. He has played a pivotal role in pioneering novel cancer therapies for companion animals, including ONCEPT® (a registered trademark of Boehringer Ingelheim Animal Health) which is a fully licensed canine melanoma vaccine, and contributing to the development and evaluation of cutting-edge treatment modalities in his previous role as Global Director of Clinical Studies for Mars Veterinary Health and VCA. He is an adjunct faculty member of the Memorial Sloan-Kettering Cancer Center and has served as Chair of the American College of Veterinary Internal [...]

jwiley2025-05-23T13:05:23-05:00April 10th, 2025|

ELIAS Animal Health Announces Apheresis Partnership with CTAC, Expanding Access to Cancer Immunotherapy in Southeast U.S.

LENEXA, Kan., Feb. 13, 2025 -- In alignment with our commitment to expand access to innovative veterinary cancer care across the country, ELIAS Animal Health is excited to announce that the Canine Transplant and Apheresis Center (CTAC) in Chattanooga, Tennessee is now providing apheresis services to veterinary patients undergoing the ELIAS Cancer Immunotherapy (ECI®). CTAC is located inside the Pullen Cancer Center at VCSG. ECI® is an adoptive cell therapy that harnesses the dog’s own immune system to identify and attack cancer cells. Apheresis is a critical step in the ECI® treatment protocol, which is a one-time procedure used to collect primed immune cells for activation and expansion. This new partnership enables broader access for veterinarians and pet owners interested in pursuing ECI® to treat cancer in dogs in the southeast region of the United States. Questions about treatment and patient referrals should be directed to ELIAS Animal Health. The decision [...]

jwiley2025-02-13T15:26:35-06:00February 13th, 2025|

ELIAS Animal Health Conducting Limb-Sparing Canine Osteosarcoma Clinical Study with Grant from Morris Animal Foundation

LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has initiated a new study evaluating the company’s adoptive T cell therapy—the ELIAS Cancer Immunotherapy (ECI®)—in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs suffering from appendicular osteosarcoma. The study, which is funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri. “For dogs with appendicular osteosarcoma, amputation of the affected limb followed by chemotherapy is the typical standard of care. However, in certain cases amputation may not be appropriate,” said ELIAS Chief Medical Officer Noe Reyes, DVM. “In this study, we’re evaluating a new approach where the dog is treated with the limb-sparing surgery followed by ECI® immunotherapy.” The study will assess the safety and efficacy [...]

jwiley2024-07-31T07:12:52-05:00July 31st, 2024|

ELIAS Animal Health Expands Manufacturing Capacity Ahead of Product Approval and Pipeline Expansion

OLATHE, Kan., April 30, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, is expanding its manufacturing capacity in a larger facility located in Lenexa, Kansas as it prepares for the commercial product launch of the ELIAS Cancer Immunotherapy (ECI®) later this year. In January 2024, ECI® was determined by the USDA as demonstrating a reasonable expectation of efficacy, a significant milestone in the pathway to product licensure, and a significant milestone in veterinary oncology. ECI® is poised to be the only adoptive cell therapy of its kind approved for the treatment of canine osteosarcoma, a deadly form of bone cancer in dogs. Osteosarcoma is one of the top five cancers in dogs and yet little innovation has been achieved in treating this disease. The historical standard of care for treating canine osteosarcoma has been off-label chemotherapy. With ECI®’s pioneer position as a therapy specifically indicated [...]

jwiley2025-05-23T13:03:15-05:00April 30th, 2024|

ELIAS Animal Health Appoints Chief Revenue Officer; Launches Fundraising Round to Support Commercialization and Development of Innovative Canine Cancer Therapies

Experienced executive will lead launch of the first USDA-approved immunotherapy for the treatment of bone cancer in dogs OLATHE, Kan., April 10, 2024 /PRNewswire/ -- ELIAS Animal Health, a leading companion animal cancer therapeutics company, today announced the appointment of Brian Segebrecht as Chief Revenue Officer in anticipation of the impending product approval of the ELIAS Cancer Immunotherapy (ECI®) in Q4. Segebrecht joins the ELIAS leadership team after recently leading Sentrx Animal Care as CEO to a point of exit in 2023. At ELIAS, he will lead the commercialization of the company’s first-in-class adoptive cell therapy, as well as drive new business partnerships for the expanding product pipeline at ELIAS. “Brian’s track record of transforming commercial strategy and building value for shareholders make him the perfect fit as we move closer to the regulatory approval of ECI® in Q4 of 2024,” said Tammie Wahaus, CEO of ELIAS Animal Health. “His leadership [...]

jwiley2024-07-17T12:35:48-05:00April 10th, 2024|

About jwiley